𝔖 Bobbio Scriptorium
✦   LIBER   ✦

At the frontline of Alzheimer’s disease treatment: γ-secretase inhibitor/modulator mechanism

✍ Scribed by Taisuke Tomita

Publisher
Springer-Verlag
Year
2007
Tongue
English
Weight
184 KB
Volume
377
Category
Article
ISSN
0028-1298

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

β-secretase as a target for the treatmen
β-secretase as a target for the treatment of Alzheimer's disease
✍ Martin Citron 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 1 views

## Abstract Finding inhibitors of the first step of the amyloid cascade, Aβ~42~ generation, is a major goal of Alzheimer's disease drug development. Two target protease activities, β‐and γ‐secretase, were detected more than 10 years ago but progress in this area has been slow because the enzymes we

Boom in the development of non-peptidic
Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease
✍ Romano Silvestri 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

## Abstract β‐Amyloid cleaving enzyme‐1 (BACE1) has become a significant target for the therapy of Alzheimer's disease. After the discovery of the first non‐peptidomimetic β‐secretase inhibitors by Takeda Chemicals in 2001, several research teams focused on SAR development of these agents. The non‐